Should I buy or sell Paratek Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares. View PRTK analyst ratings or view top-rated stocks .

What is Paratek Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 1-year price objectives for Paratek Pharmaceuticals' shares. Their PRTK share price targets range from $2.15 to $5.00. On average, they anticipate the company's stock price to reach $3.58 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price. View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts .

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings data on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to analysts' expectations of $22.98 million. During the same quarter in the previous year, the company posted ($0.46) EPS.

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , SCYNEXIS (SCYX) , Dynavax Technologies (DVAX) , Matinas BioPharma (MTNB) , CBL & Associates Properties (CBL) , Inovio Pharmaceuticals (INO) , ADMA Biologics (ADMA) , Aduro Biotech (ADRO) , Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL) .

NASDAQ:PRTK

Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PRTK Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.19
▼
$2.24
50-Day Range: $2.17
▼
$2.23
52-Week Range: $1.29
▼
$3.65

Volume: 4.76 million shs
Average Volume: 724,253 shs
Market Capitalization: $127.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.58

Stock Analysis

Get Paratek Pharmaceuticals alerts:

Paratek Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 60.3% Upside
$3.58 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -2.98
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.52 out of 5 stars

Medical Sector

870th out of 918 stocks

Biotechnology Industry

38th out of 43 stocks

3.0

Analyst's Opinion

Consensus Rating
Paratek Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Paratek Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for PRTK.

0.0

Dividend Strength

Dividend Yield
Paratek Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Paratek Pharmaceuticals does not have a long track record of dividend growth.

1.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Paratek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.
Environmental Sustainability
The Environmental Impact score for Paratek Pharmaceuticals is -2.98.

N/A

News and Social Media Coverage

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.
Percentage Held by Institutions
53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Paratek Pharmaceuticals Stock (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

PRTK Stock News Headlines

March 5, 2024 | markets.businessinsider.com

Paratek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPs

February 24, 2024 | benzinga.com

Mira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and Dates

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

October 5, 2023 | finance.yahoo.com

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

September 21, 2023 | finance.yahoo.com

Novo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals

September 21, 2023 | finance.yahoo.com

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

September 19, 2023 | finance.yahoo.com

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the company

September 18, 2023 | bizjournals.com

Paratek Pharmaceuticals shareholders approve $462M buyout deal

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

September 18, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

September 12, 2023 | finance.yahoo.com

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

September 7, 2023 | finance.yahoo.com

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

August 10, 2023 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTK

August 7, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Hold Rating on Paratek Pharmaceuticals (PRTK)

August 4, 2023 | finance.yahoo.com

News Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Forecasts

August 3, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings

August 3, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

July 27, 2023 | seekingalpha.com

PRTK Paratek Pharmaceuticals, Inc.

July 11, 2023 | finance.yahoo.com

NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital

July 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Paratek Pharmaceuticals (PRTK) Neutral Recommendation

July 10, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Paratek Pharmaceuticals (PRTK)

July 10, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

July 6, 2023 | msn.com

Paratek Pharmaceuticals (PRTK) Price Target Decreased by 41.87% to 3.16

June 27, 2023 | msn.com

Paratek antibiotic Nuzyra to receive EU orphan drug status

June 27, 2023 | msn.com

Paratek investor NexPoint warns it may vote against takeover deal

June 27, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter

June 27, 2023 | finance.yahoo.com

NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital

See More Headlines

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:PRTK
Previous Symbol: NASDAQ:TSPT
CUSIP: 89354M10
CIK: 1178711
Web: www.paratekpharma.com
Phone: (617) 807-6600
Fax: 617-275-0039
Employees: 268
Year Founded: 1996

Price Target and Rating

Average Stock Price Target: $3.58
High Stock Price Target: $5.00
Low Stock Price Target: $2.15
Potential Upside/Downside: +60.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,570,000.00
Net Margins: -35.44%
Pretax Margin: -35.35%
Return on Equity: N/A
Return on Assets: -40.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.52
Quick Ratio: 0.46

Sales & Book Value

Annual Sales: $160.27 million
Price / Sales: 0.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.08) per share
Price / Book: -0.72

Miscellaneous

Outstanding Shares: 57,320,000
Free Float: 52,736,000
Market Cap: $127.82 million
Optionable: Optionable
Beta: 1.70

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Michael F. Bigham CPA (Age 65)
CPA, M.B.A., MBA, Exec. Chairman
Comp: $954.39k
Dr. Evan Loh FACC (Age 64)
FAHA, M.D., CEO & Director
Comp: $1.14M
Mr. Adam Woodrow (Age 56)
Pres & Chief Commercial Officer
Comp: $763.51k
Ms. Sarah Higgins (Age 48)
VP of Fin., Controller & Principal Accounting Officer
Mr. William M. Haskel (Age 61)
Sr. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.
Mr. Jonathan Light
Deputy Gen. Counsel & Chief Compliance Officer
Ms. Karen McGrath
Chief People Officer
Mr. Randall B. Brenner (Age 50)
Chief Devel. & Regulatory Officer

Key Competitors

View All Competitors

Insiders

PRTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Paratek Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares.
View PRTK analyst ratings or view top-rated stocks.
What is Paratek Pharmaceuticals' stock price target for 2024?: 2 equities research analysts have issued 1-year price objectives for Paratek Pharmaceuticals' shares. Their PRTK share price targets range from $2.15 to $5.00. On average, they anticipate the company's stock price to reach $3.58 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts.
How were Paratek Pharmaceuticals' earnings last quarter?: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings data on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to analysts' expectations of $22.98 million. During the same quarter in the previous year, the company posted ($0.46) EPS.
What other stocks do shareholders of Paratek Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).

This page (NASDAQ:PRTK) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis

Paratek Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About Paratek Pharmaceuticals Stock (NASDAQ:PRTK)

PRTK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders

PRTK Stock Analysis - Frequently Asked Questions

Overall MarketRank^™